Chapter 13: Opioid Analgesics — Module 1: Opioid Receptors, Endogenous Ligands, and Mechanisms of Action
1. A 58-year-old man with metastatic pancreatic cancer is receiving intravenous morphine for pain control. Thirty minutes after a dose increase, the nursing staff notes his respiratory rate has fallen to 6 breaths per minute, his oxygen saturation is 84%, and he is difficult to arouse. The attending physician administers naloxone with rapid reversal of all findings. Which opioid receptor subtype is primarily responsible for the life-threatening respiratory depression observed in this patient?
A) The delta-opioid receptor (DOR), which modulates mood and enhances mu-receptor signaling through heterodimerization but does not directly regulate brainstem respiratory rhythm
B) The kappa-opioid receptor (KOR), which mediates spinal analgesia and sedation and is the dominant receptor subtype in brainstem respiratory control centers
C) The mu-opioid receptor (MOR), which is densely expressed in brainstem respiratory centers and is the primary mediator of opioid-induced respiratory depression
D) The nociceptin opioid peptide receptor (NOP receptor), which binds nociceptin/orphanin FQ and exerts context-dependent effects at supraspinal and spinal sites
E) The zeta-opioid receptor, a proposed receptor involved in peripheral opioid growth factor binding that has not been fully characterized
ANSWER: C
Rationale:
The correct answer is C. Mu-opioid receptor (MOR) activation is the primary mechanism of opioid-induced respiratory depression. MOR is densely expressed in brainstem respiratory centers, including the pre-Bötzinger complex, which generates the respiratory rhythm, and in other medullary nuclei governing rate and depth of breathing. Morphine, a high-efficacy MOR agonist, produces dose-dependent respiratory depression through these brainstem sites; naloxone, a competitive opioid antagonist with high MOR affinity, reverses this effect rapidly, as seen in this case.
Option A: Option A is incorrect: the delta-opioid receptor (DOR) contributes to analgesia and mood modulation and enhances mu-receptor signaling through heterodimerization, but it is not the primary mediator of clinically significant respiratory depression produced by morphine or other standard opioids.
Option B: Option B is incorrect: the kappa-opioid receptor (KOR) mediates spinal analgesia, sedation, and dysphoria, but brainstem respiratory control is dominated by MOR, not KOR; furthermore, pure kappa agonists are not used clinically as primary analgesics in part because of their dysphoric profile.
Option D: Option D is incorrect: the NOP receptor binds nociceptin/orphanin FQ and importantly does not bind naloxone with meaningful affinity, which distinguishes it from the classical opioid receptors; it is not the mediator of morphine-induced respiratory depression.
Option E: Option E is incorrect: the zeta receptor is a proposed entity with peripheral growth factor binding properties that remains incompletely characterized and is not a clinical target; it has no established role in respiratory regulation.
2. A third-year medical student is reviewing the molecular pharmacology of opioids and asks her attending: "All three classical opioid receptors seem to produce analgesia through similar downstream effects — what is the primary intracellular mechanism that links receptor activation to reduced neuronal excitability?" The attending replies that the answer lies in the G-protein family these receptors preferentially couple to. Which statement most accurately describes this mechanism?
A) Opioid receptors couple primarily to Gi/Go proteins, leading to inhibition of adenylyl cyclase, reduced intracellular cyclic AMP, decreased protein kinase A activity, and consequent suppression of neuronal excitability and neurotransmitter release
B) Opioid receptors couple primarily to Gq proteins, leading to activation of phospholipase C, generation of inositol trisphosphate and diacylglycerol, and calcium release from intracellular stores that ultimately hyperpolarizes the neuron
C) Opioid receptors couple primarily to Gs proteins, leading to stimulation of adenylyl cyclase, increased cyclic AMP, and activation of protein kinase A pathways that reduce sodium channel conductance
D) Opioid receptors signal primarily through receptor tyrosine kinase pathways, transactivating epidermal growth factor receptors to produce long-lasting changes in gene expression that underlie analgesic tolerance
E) Opioid receptors function as ligand-gated ion channels that directly open chloride conductances upon agonist binding, producing rapid membrane hyperpolarization analogous to GABA-A receptor activation
ANSWER: A
Rationale:
The correct answer is A. All three classical opioid receptors — mu (MOR), kappa (KOR), and delta (DOR) — belong to the class A GPCR (G-protein-coupled receptor) family and couple preferentially to pertussis toxin-sensitive Gi/Go proteins. The primary downstream consequence of receptor activation is inhibition of adenylyl cyclase, which reduces the synthesis of cyclic AMP (cAMP). Reduced cAMP leads to decreased protein kinase A (PKA) activity, resulting in suppressed neuronal excitability, reduced voltage-gated calcium channel opening, enhanced inwardly rectifying potassium channel (GIRK) conductance, and ultimately diminished neurotransmitter release at presynaptic terminals and hyperpolarization at postsynaptic membranes. This Gi/Go-cAMP axis is the core signaling mechanism underlying opioid analgesia.
Option B: Option B is incorrect: Gq coupling activates phospholipase C and produces intracellular calcium release — this is the pathway used by Gq-coupled receptors such as alpha-1 adrenergic and muscarinic M1/M3 receptors; it is not the primary opioid signaling pathway.
Option C: Option C is incorrect: Gs stimulates adenylyl cyclase and raises cAMP — this is the opposite of opioid signaling and is the mechanism used by beta-adrenergic receptors, among others.
Option D: Option D is incorrect: opioid receptors are GPCRs, not receptor tyrosine kinases; while chronic opioid exposure does produce gene expression changes relevant to tolerance, transactivation of epidermal growth factor receptors is not the primary analgesic mechanism.
Option E: Option E is incorrect: opioid receptors are metabotropic GPCRs, not ionotropic ligand-gated channels; they do not directly gate ion conductances upon agonist binding in the manner of GABA-A or nicotinic acetylcholine receptors.
3. A pharmaceutical company is developing a novel analgesic that is a highly selective full agonist at the kappa-opioid receptor (KOR) with minimal activity at the mu-opioid receptor (MOR). Early phase I trials show adequate spinal analgesia at therapeutic doses. However, the drug fails to advance to phase II because nearly all participants in dose-escalation cohorts report severe dysphoria, anxiety, and hallucinatory experiences. Which property of KOR pharmacology most directly explains these limiting adverse effects?
A) KOR activation stimulates adenylyl cyclase through Gs coupling, raising intracellular cAMP levels in limbic circuits and triggering hyperexcitability of the amygdala and anterior cingulate cortex
B) KOR is preferentially expressed on peripheral sensory neurons and enteric neurons, and systemic exposure produces paradoxical pain sensitization through peripheral mechanisms not present with mu-selective agonists
C) KOR lacks the ability to couple to inwardly rectifying potassium channels (GIRK channels), so analgesia is achieved only at doses that simultaneously flood dopaminergic reward circuits and produce excitatory overflow
D) KOR activation in brainstem noradrenergic nuclei produces baroreceptor reflex failure and severe orthostatic hypotension, which at high doses is perceived by participants as a dysphoric near-syncopal experience
E) KOR activation in limbic system structures including the nucleus accumbens and amygdala produces dysphoria, anxiety, and psychotomimetic effects that are an intrinsic consequence of kappa agonism at these sites, distinct from the euphoric profile of MOR activation
ANSWER: E
Rationale:
The correct answer is E. The dysphoric, anxiogenic, and psychotomimetic effects of kappa-opioid receptor (KOR) agonists are well-characterized consequences of KOR activation in limbic structures, particularly the nucleus accumbens and amygdala, where KOR is prominently expressed. In contrast to mu-opioid receptor (MOR) activation, which produces euphoria and positive reinforcement through mesolimbic dopamine release, KOR activation in these same circuits produces negative affect — a pharmacological property that has been extensively studied in preclinical models of stress and depressive states. This dysphoric profile is the primary reason pure KOR agonists have not succeeded as clinical analgesics despite producing genuine analgesia at spinal and supraspinal sites.
Option A: Option A is incorrect: opioid receptors, including KOR, couple to Gi/Go proteins and inhibit adenylyl cyclase, reducing cAMP; they do not stimulate adenylyl cyclase via Gs coupling.
Option B: Option B is incorrect: while KOR is expressed peripherally, the dysphoric and psychotomimetic effects are centrally mediated, not peripheral; peripheral KOR agonism does not explain the CNS adverse effects observed in clinical trials.
Option C: Option C is incorrect: KOR, like all classical opioid receptors, does couple to GIRK channels as part of its Gi/Go effector system; the premise of this option is pharmacologically inaccurate.
Option D: Option D is incorrect: orthostatic hypotension is not a characteristic feature of kappa agonism; the dysphoric effects reported in trials are CNS phenomena including anxiety, hallucinosis, and negative affect, not cardiovascular sequelae misperceived as dysphoria.
4. A 34-year-old woman undergoing major abdominal surgery requires substantially higher postoperative morphine doses to achieve adequate analgesia compared with other patients of similar weight and renal function. Her pain team notes that she appears to metabolize morphine normally based on plasma levels. A research fellow suggests that genetic variation in the mu-opioid receptor gene may partly explain the observed difference. Which of the following best characterizes the OPRM1 A118G polymorphism and its established clinical relevance?
A) The A118G variant eliminates mu-opioid receptor expression entirely in homozygous individuals, producing a clinical phenotype of complete opioid insensitivity that requires non-opioid multimodal analgesia exclusively
B) The A118G variant results in an asparagine-to-aspartate substitution at position 40 (Asn40Asp) that alters receptor-ligand binding affinity; it has been associated with variable analgesic requirements and opioid use disorder risk in multiple studies, though effect sizes are modest and routine clinical genotyping is not standard practice
C) The A118G variant produces constitutive receptor activation through a gain-of-function mechanism, explaining why some patients require opioid antagonists rather than agonists to control postoperative pain syndromes
D) The A118G variant affects only kappa-opioid receptor expression through a shared promoter region, and its association with morphine requirements reflects kappa-mediated compensation rather than any direct effect on mu-receptor function
E) The A118G variant alters CYP2D6 metabolism of morphine to morphine-6-glucuronide, accounting for reduced active metabolite generation and thereby explaining higher dose requirements in carriers
ANSWER: B
Rationale:
The correct answer is B. The OPRM1 A118G single-nucleotide polymorphism is the most studied genetic variant affecting mu-opioid receptor (MOR) function. It results in an amino acid substitution at position 40 of the receptor protein — asparagine to aspartate (Asn40Asp) — which alters the N-terminal glycosylation site and affects receptor-ligand binding affinity, particularly for beta-endorphin. Multiple clinical studies have associated this variant with differences in analgesic opioid requirements, pain sensitivity, and risk for opioid use disorder. However, effect sizes are modest in most populations, findings have not been consistent across all studies, and routine genotyping of OPRM1 is not currently standard clinical practice. This variant offers a plausible partial explanation for the variable morphine requirements observed in this patient, but it is not deterministic.
Option A: Option A is incorrect: A118G does not eliminate receptor expression; it modifies binding affinity. Homozygous carriers do not exhibit complete opioid insensitivity — this is a pharmacologically inaccurate characterization of the polymorphism's effect.
Option C: Option C is incorrect: A118G is not a gain-of-function variant causing constitutive activation; it is a binding-affinity modifier, and no clinical syndrome of constitutive MOR activation requiring antagonists has been described from this polymorphism.
Option D: Option D is incorrect: A118G is a variant in OPRM1, which encodes the mu-opioid receptor specifically; it does not affect kappa-opioid receptor expression. The two receptors are encoded by separate genes (OPRM1 vs. OPRK1).
Option E: Option E is incorrect: A118G is a receptor variant, not a metabolic enzyme variant; CYP2D6 is the relevant enzyme for codeine-to-morphine conversion, not for morphine itself. Morphine is primarily glucuronidated by UGT enzymes, and A118G has no effect on this metabolic pathway.
5. A 62-year-old man with chronic low back pain has been on long-term oral morphine. His pain management team notes that after several weeks at a stable dose, the duration and intensity of analgesia have progressively diminished, requiring dose escalation to maintain the original effect. The team is discussing the molecular events that initiate this process of opioid tolerance. Which of the following best describes the early cellular mechanism by which continued mu-opioid receptor (MOR) activation leads to functional receptor desensitization?
A) Prolonged MOR activation depletes the intracellular pool of Gi alpha subunits through proteasomal degradation, leaving receptors structurally intact but unable to transduce signals because no coupling proteins remain available
B) Sustained MOR stimulation triggers upregulation of adenylyl cyclase isoforms through a compensatory transcriptional mechanism, so that even with continued receptor activation, cAMP levels return to or exceed baseline, overcoming the inhibitory signal
C) Continuous MOR activation leads to receptor dimerization with delta-opioid receptors (DOR), forming heterodimers with reduced agonist affinity that are constitutively internalized regardless of ligand occupancy
D) G-protein-coupled receptor kinases (GRKs) phosphorylate the activated MOR at intracellular serine and threonine residues, recruiting beta-arrestin proteins that sterically uncouple the receptor from Gi/Go signaling and target it for clathrin-mediated internalization
E) Tolerance develops because morphine itself is converted by neuronal CYP3A4 to a pharmacologically inactive N-demethylated metabolite that competitively occupies MOR without activating it, producing a pharmacokinetic pseudo-tolerance driven by metabolite accumulation
ANSWER: D
Rationale:
The correct answer is D. Receptor desensitization is the primary early cellular mechanism of opioid tolerance. Following sustained agonist occupancy, G-protein-coupled receptor kinases (GRKs) — particularly GRK2 and GRK3 — phosphorylate the activated mu-opioid receptor (MOR) at multiple serine and threonine residues on its intracellular C-terminal tail and third intracellular loop. This phosphorylation markedly increases the receptor's affinity for beta-arrestin proteins (beta-arrestin 1 and 2). Once bound, beta-arrestin sterically occludes the receptor-G-protein interface, functionally uncoupling MOR from Gi/Go signaling without displacing the agonist. Arrestin binding also recruits clathrin and AP-2 adaptor proteins, initiating receptor internalization into endosomes. Depending on subsequent trafficking — recycling to the plasma membrane versus lysosomal degradation — the net effect is reduced surface receptor availability and diminished signaling efficiency, collectively manifesting as tolerance. This GRK-arrestin-internalization sequence is the canonical molecular basis for acute MOR desensitization.
Option A: Option A is incorrect: Gi alpha subunits are not depleted by proteasomal degradation during tolerance; the G-proteins themselves remain available. The uncoupling occurs at the receptor-G-protein interface mediated by arrestin, not through G-protein loss.
Option B: Option B is incorrect: while adenylyl cyclase superactivation (AC sensitization) does occur with chronic opioid exposure and contributes to dependence, it is a later adaptive mechanism, not the initial desensitization event; furthermore, this mechanism reflects compensatory cAMP overshoot upon agonist withdrawal rather than the reduction of analgesic effect during continued administration.
Option C: Option C is incorrect: while MOR-DOR heterodimerization is pharmacologically real and can modify receptor trafficking, constitutive internalization of MOR-DOR heterodimers regardless of ligand occupancy is not the primary mechanism of morphine tolerance; this option misrepresents the heterodimerization literature.
Option E: Option E is incorrect: opioid tolerance is a pharmacodynamic phenomenon, not a pharmacokinetic one; N-demethylated morphine metabolites do not accumulate as competitive antagonists at MOR, and neuronal CYP3A4 activity is not the driver of clinical morphine tolerance.
6. A neuroscience fellow is presenting a case conference on a patient with refractory cancer pain who responded dramatically to intrathecal morphine after failing systemic opioids. The fellow explains that the PAG-RVM (periaqueductal gray–rostral ventromedial medulla) circuit is critical to understanding how supraspinal opioid administration produces analgesia at distant spinal sites. Which mechanism most accurately accounts for this supraspinal-to-spinal analgesic relay?
A) Opioid activation of MOR in the periaqueductal gray (PAG) stimulates direct glutamatergic projections to spinal dorsal horn neurons, producing excitatory postsynaptic potentials in lamina I interneurons that inhibit pain transmission by lateral inhibition
B) MOR activation in the PAG enhances noradrenergic projections exclusively from the locus coeruleus directly to spinal cord laminae I and II without involvement of the rostral ventromedial medulla (RVM), releasing norepinephrine that activates alpha-1 receptors on dorsal horn neurons
C) MOR activation in the PAG disinhibits output neurons projecting to the rostral ventromedial medulla (RVM), which in turn sends serotonergic and noradrenergic projections down the dorsolateral funiculus to inhibit nociceptive transmission in spinal cord dorsal horn laminae I and II
D) Opioids activate MOR on supraspinal astrocytes in the PAG, which release adenosine that diffuses retrograde into blood vessels, is carried systemically to the spinal cord, and suppresses dorsal horn calcium currents through adenosine A1 receptors
E) PAG neurons express constitutively active GABA-B receptors that are silenced by opioid-induced endogenous endorphin release, removing tonic GABAergic suppression of spinal cord projection neurons and paradoxically increasing descending facilitation that the intrathecal drug then blocks locally
ANSWER: C
Rationale:
The correct answer is C. The PAG-RVM descending inhibitory system is the classic supraspinal analgesic circuit activated by opioids. At the level of the periaqueductal gray (PAG), GABAergic interneurons tonically inhibit the output neurons that project to the rostral ventromedial medulla (RVM). MOR activation in the PAG inhibits these GABAergic interneurons (disinhibition), releasing the PAG output neurons from tonic suppression. The now-active PAG-RVM projection activates ON and OFF cells in the RVM, with net activation of descending inhibitory pathways that travel in the dorsolateral funiculus. These descending projections release serotonin (5-HT) and norepinephrine (NE) onto spinal cord dorsal horn neurons in laminae I and II, inhibiting nociceptive transmission from primary afferents. This is why intrathecal morphine, which acts directly at spinal MORs without engaging the supraspinal circuit, can be highly effective even in patients who respond incompletely to systemic opioids.
Option A: Option A is incorrect: the PAG-to-spinal pathway is inhibitory and works through descending modulatory systems, not through direct glutamatergic excitation of spinal inhibitory interneurons; this option mischaracterizes both the transmitter type and the circuit direction.
Option B: Option B is incorrect: while the locus coeruleus does send noradrenergic projections to the dorsal horn and contributes to opioid analgesia, the primary relay nucleus for PAG-mediated descending inhibition is the RVM; the pathway is not exclusively noradrenergic and does not bypass the RVM as stated.
Option D: Option D is incorrect: opioid-induced analgesia through the PAG is a neuronal circuit mechanism, not an astrocyte-adenosine-bloodstream relay; this option describes a pharmacologically implausible systemic diffusion mechanism.
Option E: Option E is incorrect: this option inverts the logic of the circuit; the analgesic disinhibition in the PAG involves GABAergic interneurons being suppressed, releasing excitatory output neurons that activate descending inhibition — not a mechanism that paradoxically increases descending facilitation.
7. An anesthesiologist is counseling a patient before posterior spinal fusion surgery about the difference between systemic opioids and neuraxial analgesia. She explains that intrathecal and epidural opioids work by directly accessing the primary site of spinal nociceptive processing. At which anatomical location in the spinal cord do opioids exert their most important direct spinal analgesic effect, and what is the primary mechanism at that site?
A) Opioids act predominantly on mu-opioid receptors concentrated in laminae I and II of the dorsal horn (the substantia gelatinosa), where presynaptic MOR activation inhibits calcium-dependent neurotransmitter release from primary afferent C and A-delta fibers, and postsynaptic MOR activation hyperpolarizes dorsal horn projection neurons via GIRK channel opening
B) Opioids act predominantly on mu-opioid receptors in the ventral horn motor neuron pools, suppressing the motor reflex arcs that amplify perceived pain intensity through muscle spasm and abnormal posturing, with the analgesic benefit being entirely indirect
C) Opioids act on MOR expressed exclusively in the intermediolateral cell column of the thoracic spinal cord, where they suppress sympathetic preganglionic neuron activity that would otherwise amplify nociceptive signaling via peripheral norepinephrine release at pain receptors
D) Spinal opioid analgesia is mediated through sigma receptors in the deep dorsal horn laminae IV and V, which modulate wide-dynamic-range neuron activity; laminae I and II are not significant opioid targets because primary afferents terminate too superficially for effective drug penetration from the intrathecal space
E) Neuraxial opioids act primarily on the central canal ependymal cells that line the spinal cord, which express high-density MOR and release inhibitory neuropeptides that diffuse laterally into the dorsal horn over several hours, explaining the delayed peak effect of intrathecal morphine
ANSWER: A
Rationale:
The correct answer is A. The substantia gelatinosa — laminae I and II of the dorsal horn — is the primary site of spinal opioid analgesia. This region receives direct input from primary afferent C fibers (unmyelinated, slow pain) and A-delta fibers (thinly myelinated, fast sharp pain). MOR is highly concentrated in both laminae, expressed presynaptically on the central terminals of these afferent neurons and postsynaptically on dorsal horn interneurons and projection neurons. Presynaptic MOR activation inhibits voltage-gated calcium channel opening, reducing calcium influx and thereby suppressing release of substance P, glutamate, and other pain-signaling transmitters from primary afferent terminals. Postsynaptic MOR activation opens GIRK channels (inwardly rectifying potassium channels), hyperpolarizing dorsal horn neurons and raising the threshold for action potential generation and ascending nociceptive transmission. These dual pre- and postsynaptic mechanisms make laminae I/II the mechanistic core of spinal opioid analgesia.
Option B: Option B is incorrect: opioids do not exert their primary spinal analgesic effect on ventral horn motor neurons; while muscle relaxation may provide secondary comfort, this is not the mechanism of neuraxial opioid analgesia.
Option C: Option C is incorrect: the intermediolateral cell column governs sympathetic preganglionic outflow and is not the primary site of spinal opioid analgesia; this option conflates autonomic spinal pathways with nociceptive dorsal horn circuits.
Option D: Option D is incorrect: sigma receptors are pharmacologically distinct from classical opioid receptors and are not the primary mediators of opioid analgesia; laminae I and II are in fact the most MOR-dense regions of the dorsal horn, and intrathecal drug delivery directly bathes these superficial laminae.
Option E: Option E is incorrect: ependymal cells lining the central canal are not the primary site of opioid action; this fabricated mechanism has no established pharmacological basis.
8. A first-year resident asks during morning rounds: "When the body releases its own opioid peptides in response to pain or stress, how do different endogenous ligands differ in which receptors they activate — and does this matter clinically?" The attending replies that receptor selectivity among the endogenous opioids is real but not absolute, and that understanding it explains certain physiological and clinical observations. Which of the following correctly pairs an endogenous opioid peptide family with its primary receptor preference and a corresponding physiological role?
A) The dynorphins, derived from prodynorphin (also called proenkephalin B), are the endogenous ligands with highest selectivity for the mu-opioid receptor (MOR); their prominent role in the mesolimbic reward system explains why stress activates euphoric rather than aversive neural circuits
B) Met-enkephalin and leu-enkephalin, derived from proenkephalin A, are the principal endogenous ligands for the kappa-opioid receptor (KOR) and are primarily responsible for opioid-mediated diuresis and the dysphoric response to severe stress
C) Beta-endorphin, derived from proopiomelanocortin (POMC), has selectivity for the mu-opioid receptor (MOR) and delta-opioid receptor (DOR) but not for kappa-opioid receptor (KOR); it is released from the anterior pituitary and hypothalamic neurons and mediates stress-induced analgesia
D) Nociceptin (orphanin FQ), derived from pronociceptin, has high affinity for all three classical opioid receptors (MOR, KOR, DOR) and for the NOP receptor, making it the most promiscuous of the endogenous opioids with the broadest spectrum of analgesic and anti-analgesic effects
E) Beta-endorphin, derived from proopiomelanocortin (POMC) and released from the anterior pituitary and arcuate nucleus during stress, has high affinity for both mu-opioid receptors (MOR) and delta-opioid receptors (DOR), while the dynorphins, derived from prodynorphin, are the principal endogenous kappa-opioid receptor (KOR) ligands and contribute to stress-induced dysphoria
ANSWER: E
Rationale:
The correct answer is E. The endogenous opioid peptide system comprises four main families, each with a precursor protein and characteristic receptor selectivity. Beta-endorphin is derived from proopiomelanocortin (POMC) — the same large precursor that gives rise to ACTH and MSH — and is released from the anterior pituitary (into the bloodstream) and from POMC-containing neurons in the arcuate nucleus of the hypothalamus (into the CNS). Beta-endorphin has high affinity for both MOR and DOR and is the principal mediator of stress-induced and exercise-induced analgesia. The dynorphins (dynorphin A, dynorphin B, and related peptides) are derived from prodynorphin (also called proenkephalin B) and are the primary endogenous ligands for the kappa-opioid receptor (KOR). KOR activation by dynorphins in limbic circuits contributes to the aversive, dysphoric component of stress — part of the neurobiological basis for stress-induced negative affect and its role in addiction vulnerability.
Option A: Option A is incorrect: the dynorphins are the principal KOR ligands, not MOR ligands; KOR activation in limbic circuits produces dysphoria, not euphoria — this option inverts both the receptor selectivity and the functional consequence.
Option B: Option B is incorrect: met-enkephalin and leu-enkephalin, derived from proenkephalin A (proenkephalin), preferentially bind DOR and to a lesser extent MOR; they are not the principal KOR ligands and are not the primary mediators of opioid-induced diuresis (which is a KOR/dynorphin effect via antidiuretic hormone suppression).
Option C: Option C is incorrect about KOR affinity: beta-endorphin does indeed have low affinity for KOR relative to MOR and DOR; however, the option as stated is largely accurate except that it omits the important pairing of dynorphins with KOR, which is the pharmacologically critical parallel; the most complete and clinically informative answer requires both pairings.
Option D: Option D is incorrect: nociceptin (orphanin FQ) is the endogenous ligand for the NOP receptor specifically; it does not bind the three classical opioid receptors (MOR, KOR, DOR) with meaningful affinity, which is precisely what made it the "orphan" receptor ligand when first cloned in 1994.
9. A pharmacology lecturer is explaining to residents why opioids can simultaneously reduce pain signal transmission at presynaptic terminals and reduce neuronal firing at postsynaptic sites. She states that both effects derive from the same G-protein coupling mechanism but through distinct downstream ion channel targets. Which of the following correctly identifies both effector mechanisms and the direction of their ion channel effects that together explain opioid-mediated neuronal inhibition?
A) Gi/Go activation opens voltage-gated sodium channels (Nav) at presynaptic terminals, reducing the action potential threshold and slowing conduction velocity, while postsynaptically closing AMPA glutamate receptors through phosphorylation, thereby blocking excitatory synaptic transmission
B) Gi/Go activation inhibits voltage-gated calcium channels (Cav) at presynaptic terminals, reducing calcium influx and suppressing neurotransmitter release, while simultaneously activating inwardly rectifying potassium channels (GIRK channels) postsynaptically, increasing potassium efflux and hyperpolarizing the neuron
C) Gi/Go activation closes voltage-gated potassium channels (Kv) at presynaptic terminals, prolonging depolarization and paradoxically enhancing calcium-independent vesicular fusion, while postsynaptically opening chloride channels similar to GABA-A receptors to produce hyperpolarization
D) Gi/Go activation directly gates NMDA glutamate receptors at presynaptic terminals by removing the magnesium block from the channel pore, allowing calcium entry that triggers endocannabinoid retrograde inhibition of the same synapse in a self-limiting feedback loop
E) Gi/Go activation phosphorylates HCN channels (Ih current) at presynaptic terminals through protein kinase C, hyperpolarizing the resting membrane potential and shifting the activation threshold for dendritic action potentials, while postsynaptically blocking substance P receptors (NK1) by allosteric competition
ANSWER: B
Rationale:
The correct answer is B. The two principal ion channel effectors downstream of opioid receptor Gi/Go activation are voltage-gated calcium channels and inwardly rectifying potassium (GIRK) channels, and their effects are mechanistically complementary. Presynaptically, Gi/Go beta-gamma subunits directly inhibit N-type and P/Q-type voltage-gated calcium channels (Cav2.2 and Cav2.1) at synaptic terminals. The resulting reduction in calcium influx during the action potential decreases the probability of synaptic vesicle fusion and release of nociceptive neurotransmitters, including substance P and glutamate, from primary afferent terminals in the dorsal horn. Postsynaptically, Gi/Go also activates GIRK channels (G-protein-coupled inwardly rectifying potassium channels, particularly Kir3 family). GIRK channel opening increases membrane potassium conductance, driving the membrane potential toward the potassium equilibrium potential (approximately -90 mV), well below the action potential threshold. This hyperpolarization reduces postsynaptic excitability and raises the threshold for firing of dorsal horn projection neurons. The combination of reduced neurotransmitter release (presynaptic) and reduced postsynaptic excitability (postsynaptic) explains why opioids are highly effective at spinal and supraspinal nociceptive synapses.
Option A: Option A is incorrect: Gi/Go coupling does not open voltage-gated sodium channels — opening Nav channels would increase excitability, which is the opposite of opioid effect; AMPA receptor phosphorylation is not a direct effector of Gi/Go signaling.
Option C: Option C is incorrect: opioids close calcium channels and open potassium channels — closing potassium channels would prolong depolarization and enhance neurotransmitter release, which is precisely the opposite of opioid action; opioid receptors do not gate chloride channels.
Option D: Option D is incorrect: removal of the NMDA receptor magnesium block is a voltage-dependent phenomenon unrelated to Gi/Go signaling; opioids do not gate NMDA receptors, and this mechanism does not describe opioid receptor pharmacology.
Option E: Option E is incorrect: HCN channel modulation by opioids through protein kinase C is not the primary effector mechanism; substance P NK1 receptors are not blocked by allosteric competition from opioids.
10. A toxicologist is consulted on a patient who received an investigational analgesic that is a co-agonist at both the mu-opioid receptor (MOR) and the nociceptin opioid peptide receptor (NOP receptor). The patient develops respiratory depression. Naloxone is administered at standard doses with partial but incomplete reversal of respiratory depression. The toxicologist explains to the team why complete reversal was not achieved. Which property of the NOP receptor most directly explains the incomplete response to naloxone?
A) The NOP receptor is a Gs-coupled receptor rather than a Gi/Go-coupled receptor; naloxone is designed to competitively antagonize only Gi-coupled opioid receptors, and its binding conformation is incompatible with Gs-coupled receptor binding pockets
B) The NOP receptor is expressed exclusively in peripheral sensory ganglia and does not reach the brainstem; its activation therefore produces peripheral respiratory effects that are anatomically inaccessible to systemically administered naloxone, which does not cross peripheral ganglionic barriers
C) The NOP receptor mediates respiratory depression through sigma receptor cross-talk rather than through direct ion channel effectors; naloxone blocks direct effector pathways but cannot interrupt sigma receptor signaling, leaving a component of depression unresolved
D) The NOP receptor does not bind naloxone with meaningful affinity; it is pharmacologically distinct from the three classical opioid receptors (MOR, KOR, DOR) in this respect, so the component of respiratory depression attributable to NOP receptor agonism cannot be reversed by naloxone administration
E) Naloxone has been shown in preclinical models to act as a partial agonist rather than a pure antagonist at the NOP receptor, so administration of naloxone paradoxically potentiates NOP-mediated respiratory depression at the doses used clinically for opioid reversal
ANSWER: D
Rationale:
The correct answer is D. The nociceptin opioid peptide receptor (NOP receptor), encoded by OPRL1, is structurally homologous to the three classical opioid receptors (MOR, KOR, DOR) — sharing approximately 50% amino acid identity — but it does not bind naloxone with meaningful affinity. This is a defining pharmacological characteristic that distinguished it as an "orphan" receptor when first cloned in 1994, because classical opioid antagonists were ineffective at displacing its ligand. The lack of naloxone affinity at NOP reflects key differences in the binding pocket, particularly in residues critical for naloxone docking that are conserved across MOR, KOR, and DOR but diverge in NOP. Cebranopadol, a dual MOR/NOP co-agonist in late-stage clinical development, provides exactly this pharmacological scenario: its MOR-mediated respiratory depression is naloxone-reversible, but any NOP receptor-mediated contribution to respiratory effects is not. In this case, partial reversal with naloxone is consistent with blocking the MOR component while leaving the NOP-mediated component unaddressed.
Option A: Option A is incorrect: the NOP receptor couples to Gi/Go proteins, the same family as the classical opioid receptors; it does not couple to Gs. Naloxone's inability to bind NOP is not explained by G-protein coupling differences.
Option B: Option B is incorrect: NOP receptor is widely expressed throughout the CNS including brainstem structures; it is not restricted to peripheral sensory ganglia, and CNS expression is pharmacologically relevant to centrally mediated effects.
Option C: Option C is incorrect: NOP receptor mediates its effects through the same Gi/Go-coupled effector system as classical opioid receptors, including GIRK channel activation and calcium channel inhibition; sigma receptor cross-talk is not the mechanism of NOP-mediated respiratory effects.
Option E: Option E is incorrect: naloxone is not a partial agonist at NOP; its failure to act at NOP is due to lack of binding affinity, not agonist activity, and it does not potentiate NOP-mediated effects clinically.
11. A 71-year-old woman with osteoporotic vertebral fractures is started on extended-release oxycodone for pain control. Within the first week she develops severe constipation unresponsive to dietary fiber and standard laxatives, requiring dose reduction and ultimately a bowel regimen including methylnaltrexone (a peripherally acting mu-opioid receptor antagonist). Which mechanism most directly accounts for why opioids cause constipation that does not resolve with tolerance as readily as other opioid side effects?
A) Systemic opioids activate mu-opioid receptors (MOR) in hypothalamic nuclei that suppress the gastrocolic reflex through a neuroendocrine pathway; because hypothalamic MOR tolerance develops more slowly than cortical MOR tolerance, the constipating effect persists while analgesic tolerance advances
B) Opioids impair intestinal motility by crossing the blood-brain barrier and suppressing the autonomic preganglionic neurons in the intermediolateral cell column, reducing parasympathetic outflow to the gut via the vagus nerve and eliminating cholinergic drive to intestinal smooth muscle
C) MOR is expressed on enteric neurons throughout the gastrointestinal tract; opioid-induced MOR activation inhibits acetylcholine release from myenteric plexus neurons, reducing coordinated peristaltic contractions, increasing non-propulsive segmental contractions, increasing sphincter tone, and increasing fluid absorption — effects that are peripherally mediated and therefore not subject to the same central tolerance mechanisms that diminish analgesic tolerance over time
D) Opioids cause constipation by activating kappa-opioid receptors (KOR) in colonic smooth muscle, producing direct smooth muscle tetanic contraction that is independent of enteric nerve activity; because colonic smooth muscle KOR expression does not downregulate with chronic exposure, tolerance never develops to this effect
E) The constipating effect of opioids is mediated entirely through spinal cord MOR activation that suppresses the defecation reflex arc; methylnaltrexone works because it cannot cross the blood-spinal cord barrier and instead acts at peripheral receptors to separate the spinal constipation mechanism from the analgesic effect
ANSWER: C
Rationale:
The correct answer is C. Opioid-induced constipation (OIC) is mediated primarily through mu-opioid receptors (MOR) expressed abundantly throughout the enteric nervous system — the intrinsic neural network of the gastrointestinal tract comprising the myenteric (Auerbach's) plexus and the submucosal (Meissner's) plexus. MOR activation in myenteric neurons inhibits the release of acetylcholine and other neurotransmitters responsible for coordinated peristalsis. The physiological consequences are multiple and additive: reduced propulsive peristaltic contractions, increased non-propulsive segmental (mixing) contractions that impede transit, increased tone of the pyloric, ileocecal, and anal sphincters, and enhanced mucosal absorption of water from intestinal contents — all of which together produce the clinical syndrome of constipation with hard, infrequent stools. Critically, because these effects are peripherally mediated and enteric neurons exist in a pharmacological environment partly shielded from the degree of receptor adaptation occurring centrally, OIC is notably resistant to tolerance compared with analgesic, sedative, and euphoric effects. This is precisely why peripherally acting MOR antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and naldemedine have therapeutic utility — they block peripheral enteric MOR without crossing the blood-brain barrier, reversing OIC without precipitating central opioid withdrawal or compromising analgesia.
Option A: Option A is incorrect: the primary locus of opioid-induced constipation is the enteric nervous system, not hypothalamic neuroendocrine pathways; differential tolerance rates between hypothalamic and cortical receptors do not explain the peripheral nature of this effect or the mechanism of action of PAMORAs.
Option B: Option B is incorrect: while opioids do reduce parasympathetic tone, the primary mechanism of OIC is direct enteric MOR activation, not suppression of autonomic preganglionic neurons in the spinal cord; furthermore, this mechanism would not explain why peripherally restricted antagonists like methylnaltrexone reverse constipation without affecting analgesia.
Option D: Option D is incorrect: opioid-induced constipation is a MOR-mediated effect, not a KOR-mediated one; KOR agonists are not the pharmacological basis of OIC and this option is mechanistically inaccurate.
Option E: Option E is incorrect: while spinal MOR activation does modulate some aspects of the defecation reflex, the primary mechanism of OIC is peripheral enteric MOR activation, not spinal; methylnaltrexone's mechanism of action is peripheral MOR blockade in the gut, not an inability to cross the blood-spinal cord barrier.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.